Larotrectinib (LOXO-101)
Author:
Publisher
Springer International Publishing
Link
http://link.springer.com/content/pdf/10.1007/978-3-319-91442-8_10
Reference37 articles.
1. Ardini E, Bosotti R, Borgia A, De Ponti C et al (2014) The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition. Mol Oncol 8:1495–1507
2. Bollig-Fischer A, Michelhaugh S et al (2015) Cytogenomic profiling of breast cancer brain metastases reveals potential for repurposing targeted therapeutics. Oncotarget 6(16):14614–14624
3. Burris H, Hong D, Shaw A, Doebele R, Bauer T et al (2015a) Pharmacokinetics (PK) of LOXO-101 during the first-in-human phase I study in patients with advanced solid tumors—interim update. Poster, presented at the AACR annual meeting 2015, Pennsylvania
4. Burris H, Brose M, Shaw A et al (2015b) A first-in-human study of LOXO-101, a highly selective inhibitor of the tropomyosin receptor kinase (TRK) family. J Clin Oncol 33(suppl): abstract TPS2624
5. Califano R, Abidin A, Tariq N et al (2015) Beyond EGFR and ALK inhibition: unravelling and exploiting novel genetic alternations in advanced non small-cell lung cancer. Cancer Treat Rev 41(5):401–411
Cited by 20 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Macrocyclic-based strategy in drug design: From lab to the clinic;European Journal of Medicinal Chemistry;2024-11
2. Induction of resistance to neurotrophic tropomyosin‐receptor kinase inhibitors by HMGCS2 via a mevalonate pathway;Cancer Medicine;2024-06
3. Novel Immunotherapy Approaches in Colorectal Cancer;Interdisciplinary Cancer Research;2024
4. Drug delivery system for the extended-release of larotrectinib based on a biocompatible Fe-based metal-organic framework: synthesis, characterization, in vitro release properties and antitumor evaluation;Frontiers in Bioengineering and Biotechnology;2023-06-01
5. Challenges and Therapeutic Opportunities in the dMMR/MSI-H Colorectal Cancer Landscape;Cancers;2023-02-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3